MCIM
APLS

Meadow Creek Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

Meadow Creek Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$18K Buy
+736
New +$20.3K ﹤0.01% 1326
2019
Q1 		– Sell
-1,296
Closed -$17K – 1343
2018
Q4 		$17K Buy
+1,296
New +$19.9K ﹤0.01% 1272

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Meadow Creek Investment Management's APLS Position: Q3 2019 in Review

Meadow Creek Investment Management opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2019: 736 shares worth $18K. The stake represents ﹤0.01% of the portfolio and ranks #1326 among its holdings. This is a return to the name: Meadow Creek Investment Management previously reported a position in APLS as recently as Q4 2018.

Meadow Creek Investment Management first reported a position in APLS in Q4 2018 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold APLS as of Q3 2019.

  • Meadow Creek Investment Management held 736 shares of Apellis Pharmaceuticals worth $18K as of Q3 2019.
  • Apellis Pharmaceuticals was a new Meadow Creek Investment Management position in Q3 2019.
  • Apellis Pharmaceuticals made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1326 holding.
  • Meadow Creek Investment Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 2 quarters since.
  • 129 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.